OPENING: In an era of media sensationalism, I have come to appreciate good journalism. When it comes to healthcare, my number one choice is STAT News, but I have also found the Financial Times and The Economist to be excellent sources. Below is a summary of an in-depth article from the Finacial Times on Pfizer and their COVID vaccine. It’s beyond damning; it’s a reflection of an industry that values profits above all else.

OPENING: As the NY Times recently reported, obesity is the leading cause of mortality in the United States. Obesity costs the nation $1.72 trillion every year. Although not everyone with type 2 diabetes is overweight, obesity and an inactive lifestyle are two of the most common causes of type 2 diabetes. These things are responsible for about 90% to 95% of diabetes cases in the United States

SUMMARY: AbbVie continues to profit from Americans by repeatedly raising U.S. prices on its widely-used Humira rheumatoid arthritis drug while cutting the price abroad. AbbVie exploits the U.S. patent system to fend off competitors and increased the price of Humira to $77,000 for a year’s supply, while the price of its cancer drug Imbruvica was raised to $181,529 per year.